Park, Joon Seok http://orcid.org/0000-0003-4001-6886
Gazzaniga, Francesca S.
Kasper, Dennis L.
Sharpe, Arlene H.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01 AI56299)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5F32CA247072-02)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (5T32HD55148-10)
Quark Ventures A31696
Article History
Received: 2 February 2023
Revised: 11 July 2023
Accepted: 19 July 2023
First Online: 11 September 2023
Competing interests
: A.H.S. currently has funding from Quark, AbbVie, Moderna and Erasca unrelated to this Review. A.H.S. serves on advisory boards for SQZ Biotechnologies, Selecta, Elpiscience, Monopteros, Bicara, Fibrogen, IOME, Alixia, Corner Therapeutics, Bioventre, Glaxo Smith Kline, Amgen, and Janssen. She is also on scientific advisory boards for the Massachusetts General Cancer Center, Program in Cellular and Molecular Medicine at Boston Children’s Hospital, the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, the Gladstone Institute, and the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy. She is an academic editor for the Journal of Experimental Medicine. A.H.S. has patents/pending royalties on the PD-1 pathway from Roche and Novartis.